JaxBio Technologies

Company Overview

Snapshot

Founded in January 2022 by Shahar Zirkin, Joel Bar-El, and Dror Feldheim, JaxBio Technologies operates with 11–50 employees. The company has raised $17.98M across three funding rounds. In July 2024, JaxBio Technologies secured a grant from the European Innovation Council Accelerator.

Business overview

JaxBio Technologies is a Health Tech & Life Sciences company focused on revolutionizing cancer diagnosis and management through a sensitive blood test. The company has developed an ultra-sensitive method to detect genetic and epigenetic profiles in cell-free DNA, which are indicative of cancer initiation and progression. This proprietary process extracts cell-free DNA from blood samples, labels markers, and hybridizes the DNA onto a custom chip to identify unique pixel pattern signatures for classifying cancer type and stage. JaxBio is currently developing its initial diagnostic tests for lung cancer and hematological malignancies, serving the global market.

Strategic signal

In July 2024, JaxBio Technologies secured a €2.5M grant from the European Innovation Council Accelerator. This significant non-equity funding validates the company's innovative approach to early cancer diagnosis and provides crucial capital to accelerate the development of its blood-based diagnostic tests, signaling strong institutional confidence in its technology and market potential.

Company Intelligence Q&A

What is JaxBio Technologies' primary focus?

JaxBio Technologies is focused on developing a simple and sensitive blood test for the early detection, monitoring, and prediction of treatment response for various cancers, including lung cancer and hematological malignancies.

When was JaxBio Technologies founded and by whom?

JaxBio Technologies was founded in January 2022 by Shahar Zirkin, Joel Bar-El, and Dror Feldheim.

What significant funding did JaxBio Technologies receive in July 2024?

In July 2024, JaxBio Technologies secured a €2.5M grant from the European Innovation Council Accelerator.

What technology does JaxBio Technologies utilize for cancer detection?

JaxBio Technologies utilizes an ultra-sensitive method to detect genetic and epigenetic profiles in cell-free DNA from blood samples. This involves fluorescently labeling markers and hybridizing the DNA onto a custom chip to identify unique pixel pattern signatures for cancer classification.

What was the nature of the funding received in January 2023?

In January 2023, JaxBio Technologies received a grant from Horizon Europe to support the creation of array-based cancer tests.